To assess the efficacy of anti-IL-1β therapeutics in our severe COVID-19 mouse model, we administered a single dose of IL-1β-neutralising monoclonal antibodies, analogous to the clinically used human antibody Canakinumab, to 10- to 12-week-old WT mice on the day of infection with P21. Here, IL1B is linked to COVID-19.